Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia
Authors
Keywords
Glycine transporter 1 inhibitor, Schizophrenia, Negative symptoms, Cognitive dysfunction, TASP0315003
Journal
PSYCHOPHARMACOLOGY
Volume 232, Issue 15, Pages 2849-2861
Publisher
Springer Nature
Online
2015-04-14
DOI
10.1007/s00213-015-3920-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Novel Object Recognition Test in Rodents in Relation to Cognitive Impairment in Schizophrenia
- (2014) Lakshmi Rajagopal et al. CURRENT PHARMACEUTICAL DESIGN
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia
- (2014) Joep H. Schoemaker et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
- (2013) Chih-Chia Huang et al. BIOLOGICAL PSYCHIATRY
- Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond
- (2013) John H. Krystal et al. BIOLOGICAL PSYCHIATRY
- A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease
- (2012) Katsuya Harada et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Role of 5-Hydroxytryptamine 7 Receptors in the Phencyclidine-Induced Novel Object Recognition Deficit in Rats
- (2011) M. Horiguchi et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
- (2011) Daniela Alberati et al. NEUROPHARMACOLOGY
- Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex
- (2011) David JG Watson et al. NEUROPSYCHOPHARMACOLOGY
- Current pharmacological models of social withdrawal in rats
- (2010) Anand Gururajan et al. BEHAVIOURAL PHARMACOLOGY
- d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats
- (2010) Toshiharu Shimazaki et al. PSYCHOPHARMACOLOGY
- Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia
- (2010) Elizabeth Hanson et al. Current Psychiatry Reports
- A randomized, double-blind, placebo-controlled comparison study of sarcosine ( N-methylglycine) and d-serine add-on treatment for schizophrenia
- (2009) Hsien-Yuan Lane et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia☆
- (2008) D BOULAY et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats
- (2007) Jun-ichi Karasawa et al. BEHAVIOURAL BRAIN RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation